PHAT

Phathom Pharmaceuticals, Inc.
CAPPED RATING

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals, Inc. (PHAT) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B (3.3) B+ (3.8) B+ (3.7) D+ (1.6) C+ (2.6) B- (3.0)
2026-11-07 B (3.3) A- (3.9) B+ (3.7) D (1.5) C+ (2.7) B- (3.0)
2026-10-31 B (3.4) A- (3.9) A- (3.9) D (1.4) C+ (2.7) B- (3.1)
2026-10-24 B (3.3) A- (4.0) B+ (3.8) D- (1.1) C+ (2.6) B- (3.0)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe